Formycon

Formycon AG is a pharmaceutical company based in Planegg, Germany, specializing in the development and marketing of biosimilar products. Established in 1999, the company has a diverse pipeline that includes FYB201, a biosimilar candidate for Lucentis, which has completed Phase III clinical trials for treating serious eye diseases such as neovascular age-related macular degeneration. Additionally, Formycon is developing FYB202, a biosimilar for Stelara, aimed at treating inflammatory diseases including psoriasis and Crohn's disease, currently in Phase I trials. Another candidate, FYB203, targets Eylea, also used for eye conditions. The company's focus extends to drug delivery systems and it also provides comprehensive analytical and formulation services to the biopharmaceutical industry, including pre-formulation, GMP quality control, and stability testing. Formycon is committed to advancing treatments in ophthalmology, immunology, and other chronic diseases while also offering diagnostic laboratory services.